La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Pinstripes Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Pinstripes Holdings..

Pinstripes Holdings (OTC:PNST) Azioni, Catena delle Opzioni

Pinstripes Holdings

Pinstripes Holdings Inc is an experiential dining and entertainment concept combining exceptional Italian-American cuisine with bowling, bocce, and private events. It owns and operates around 17 restaurants in the USA. The company designs and constructs large-format locations that are each 26,000 to 38,000 square feet of interior space, plus additional outdoor patio space that includes outdoor dining, bocce courts, fire-pits, and decorative fountains.

PINSTRIPES HOLDINGS INC A by Pinstripes Holdings Inc.

Pinstripes Holdings Inc

Pinstripes Holdings Inc Warrants (30/09/2028)

Barclays analyst Tim Long maintains Juniper Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) with a Equal-Weight and raises the price target from $39 to $40.

News

Price Target

Analyst Ratings

JNPR

Barclays Maintains Equal-Weight on Juniper Networks, Raises Price Target to $40

Thumzup Currently Holds 19.106 BTC with a Market Value of Approximately $1.8 Million as of May 4, 2025
The Company's Board of Directors has Authorized Thumzup to Hold Up to 90% of its Liquid Assets&nbsp;in Bitcoin Under its BTC Reserve Strategy
LOS ANGELES, May 5, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4419513-1&amp;h=2711937094&amp;u=https%3A%2F%2Fwww.thumzupmedia.com%2F&amp;a=Thumzup+Media+Corporation">Thumzup Media Corporation</a> ("Thumzup" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>), an emerging leader in social media branding and programmatic marketing solutions, today announced that it has filed a "universal shelf" registration statement on Form S-3 with the Securities and Exchange Commission (the "SEC").
Once effective, the registration statement would allow Thumzup to raise up to an aggregate of&nbsp;$200,000,000 for additional working capital and to acquire additional Bitcoin ("BTC").
The Company has Board approval to implement a Bitcoin ("BTC") acquisition strategy, pursuant to which it may allocate up to 90% of its liquid assets to BTC. Under the terms of the offering, the Company would have the ability to raise capital in one or more offerings over the three years after the registration statement is declared effective by the SEC.&nbsp;These capital raises could include common stock, preferred stock (including in the form of depositary shares), warrants, debt securities (including convertible debt), purchase contracts, and/or units (which are typically a combination of two or more types of securities (global securities)).&nbsp;

Offerings

TZUP

Thumzup Media Files $200M Shelf Registration For Working Capital And To Further Its Bitcoin Treasury Strategy; Board Of Directors Has Authorized Thumzup To Hold Up To 90% Of Its Liquid Assets In Bitcoin Under Its BTC Reserve Strategy

Barclays analyst David Strauss maintains Huntington Ingalls Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) with a Equal-Weight and raises the price target from $200 to $235.

Barclays Maintains Equal-Weight on Huntington Ingalls Indus, Raises Price Target to $235

Biotech

General

MMSI

Merit Medical Releases 12-Month Efficacy Results For Single-Arm Arteriovenous Graft Cohort Of WRAPSODY Arteriovenous Efficacy Trial

Barclays analyst Adrienne Yih maintains Groupe Dynamite (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GRGD#TSX">GRGD</a>) with a Equal-Weight and raises the price target from C$14 to C$15.

TSX:GRGD

Barclays Maintains Equal-Weight on Groupe Dynamite, Raises Price Target to C$15

Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) on Monday announced it has added 1,895 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to its corporate treasury for $180.3 million, paying an average of $95,167 per BTC. 
As of May 4, the company <a href="https://assets.contentstack.io/v3/assets/bltf8d808d9b8cebd37/blt530624966fb17ac3/6818a606cc0bf423515ffcad/form-8-k_05-05-2025.pdf">holds</a> 555,450 BTC acquired for $38.08 billion at an average cost basis of $68,550 per coin.
The acquisition extends Strategy's lead as the largest public corporate holder of Bitcoin, now owning over 2.6% of the total circulating supply.
According to its latest disclosures, the company's Bitcoin holdings have delivered a year-to-date yield of 14.0% in 2025.
The announcement coincides with a broader surge in institutional investment into digital assets. 
<a href="https://blog.coinshares.com/volume-232-digital-asset-fund-flows-weekly-report-4f8ae30ba289">According</a> to CoinShares, digital asset investment products saw $2 billion in net inflows last week—the third consecutive week of positive flows.
Over the past three weeks, crypto products have attracted $5.5 billion in total inflows, reversing nine straight weeks of outflows and pushing year-to-date flows to $5.6 billion.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45191302/corporations-will-pour-330-billion-into-bitcoin-by-2029-bernstein">Corporations Will Pour $330 Billion Into Bitcoin By 2029: Bernstein</a>
Bitcoin was the primary recipient, drawing $1.8 billion in new capital last week alone. 
Bearish positions in Bitcoin also saw their largest increase since mid-December, with $6.4 million in inflows, indicating hedging activity alongside bullish sentiment.
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) investment products recorded $149 million in inflows, marking the second straight week of gains and bringing the two-week total to $336 million. 
Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) added $6 million, while smaller flows were observed into Ripple&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) ($10.5 million) and Tezos (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xtz/usd">XTZ</a>) ($8.2 million). 
Blockchain equities saw inflows of $15.9 million.
Regionally, the United States led with $1.9 billion in inflows, followed by Germany ($47 million), Switzerland ($34 million), and Canada ($20 million), indicating broad support for the asset class globally.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45165364/aptos-eyes-real-world-utility-beyond-nfts-and-defi-says-ecosystem-head-ash-pampati">Aptos Eyes Real-World Utility Beyond NFTs And DeFi, Says Ecosystem Head Ash Pampati</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

$XRP

$XTZ

MSTR

Strategy Acquires 1,895 BTC For $180 Million As Bitcoin ETFs Bounce Back With $1.8 Billion Inflow

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Fubotv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>)</h3>
<ul>
<li>On May 2, the company posted weak quarterly revenue. Revenue of the sports-first live TV streaming platform grew 8.1% year over year to $405.96 million, marginally missing the analyst consensus estimate of $415.45 million. The company's stock fell around 20% over the past five days and has a 52-week low of $1.10.</li>
<li>RSI Value: 26.9</li>
<li>FUBO Price Action: Shares of Fubotv fell 17.4% to close at $2.42 on Friday.</li>
<li>Edge Stock Ratings: 97.16 Momentum score with Value at 32.34. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/FUBO"><img loading="lazy" decoding="async" width="495" height="180" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05043130/image-2-12.png" alt="" class="wp-image-900809" style="width:349px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05043130/image-2-12.png 495w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05043130/image-2-12-300x109.png 300w" sizes="(max-width: 495px) 100vw, 495px" /></a></figure>
<h3 class="wp-block-heading">Cable One Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABO#NYSE">CABO</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On May 1, Cable One reported worse-than-expected first-quarter financial results. &#8220;We are executing on a multi-year plan to achieve sustained profitable growth in a rapidly changing and more competitive environment,&#8221; said Julie Laulis, Cable One President and CEO. &#8220;Although our residential data subscribers decreased during the quarter, we believe we have the right people, platforms and processes in place to build a customer acquisition engine that will drive meaningful growth over the long term.&#8221; The company's stock fell around 43% over the past five days and <a href="https://www.benzinga.com/quote/CABO">has a 52-week low</a> of $150.00.</li>
<li>RSI Value: 12.2</li>
<li>CABO Price Action: Shares of Cable One dipped 42.4% to close at $152.51 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505">CABO stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505"><img loading="lazy" decoding="async" width="923" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05043702/image-2-13.png" alt="" class="wp-image-900814" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05043702/image-2-13.png 923w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05043702/image-2-13-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05043702/image-2-13-768x701.png 768w" sizes="(max-width: 923px) 100vw, 923px" /></a></figure>
<h3 class="wp-block-heading">Anterix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEX#NASDAQ">ATEX</a>)</h3>
<ul>
<li>On March 10, Anterix launched its AnterixAccelerator initiative with an investment of up to $250 million. The company's stock fell around 9% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/ATEX">low of $27.37</a>.</li>
<li>RSI Value: 28.6</li>
<li>ATEX Price Action: Shares of Anterix fell 0.4% to close at $29.84 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505">ATEX shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0505"><img loading="lazy" decoding="async" width="887" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05043754/image-33.png" alt="" class="wp-image-900815" style="width:587px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05043754/image-33.png 887w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05043754/image-33-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05043754/image-33-768x721.png 768w" sizes="(max-width: 887px) 100vw, 887px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings"> Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a></li>
</ul>

Long Ideas

Markets

Media

Trading Ideas

ATEX

CABO

FUBO

Top 3 Tech And Telecom Stocks That May Jump This Quarter

Barclays analyst Dan Levy maintains General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Equal-Weight and raises the price target from $40 to $45.

Barclays Maintains Equal-Weight on General Motors, Raises Price Target to $45

In response to the academic funding cuts in the U.S. under President Donald Trump,&nbsp;France and the EU are&nbsp;preparing to roll out incentives to attract U.S.-based researchers to Europe.
What Happened: French President Emmanuel Macron and European Commission President Ursula von der Leyen are set to announce incentives for researchers considering a move to Europe.
The announcement, scheduled to be made at Sorbonne University in Paris, comes at a time when U.S. academics fear their work is under threat due to federal spending cuts and scrutiny of diversity policies in US higher education institutions, reported the Guardian.
The &#8220;Choose Europe for science&#8221; initiative was launched in response to a letter from 13 European countries, including France, Germany, and Spain, urging the EU to accelerate efforts to attract academic talent. France&nbsp;had previously launched a similar initiative, &#8220;Choose France for science&#8221;, in April.
According to Le Monde France, von der Leyen announced at Paris&#8217;s Sorbonne University that the European Union will introduce a new 500 million euro ($567 million) incentives package to make the bloc &#8220;a magnet for researchers.&#8221; 
The European Commission stated, &#8220;We have to offer the right incentives.&#8221;&nbsp;
Macron criticized restrictions on scientific research, calling them a major mistake by a leading democracy, and emphasized France's refusal to let governments dictate research topics. He also announced upcoming proposals to boost France's investment in science and research.
SEE ALSO:&nbsp;<a href="https://benzinga.com/general/entertainment/25/05/45185793/musks-ex-wife-opens-up-about-why-life-with-elon-was-so-difficult" target="_blank" rel="noreferrer noopener">Musk&#8217;s Ex-Wife Opens Up About Why Life With Elon Was So Difficult</a>
Why It Matters: The Trump administration&#8217;s stringent budget cuts have significantly impacted the U.S. education sector. The Institute of Education Sciences (IES), responsible for overseeing $800 million in education research, has been hit hard, with numerous contracts terminated by the Trump administration.
This has raised concerns about the future of education policy and data collection in the U.S.
Moreover, the Trump administration suspended $2.2 billion in grants to&nbsp;<a href="https://www.benzinga.com/25/04/44804541/trump-administration-halts-2-2-billion-in-harvard-grants-after-university-says-dont-dictate-what-we-can-teach-or-who-we-admit">Harvard University</a>&nbsp;after it refused to comply with demands to remove diversity, equity, and inclusion programs and screen international students for ideological concerns. This move has put nearly $9 billion in federal funding at risk.
These developments have created an opportunity for Europe to attract academic talent from the U.S. However, despite these efforts, the U.S. continues to outpace Europe in research investment, including private-public partnerships.
The expectation is that the pay gap between scientists in France and the U.S. will appear smaller when factoring in France&#8217;s lower education and healthcare costs, along with its more generous social benefits.
READ MORE:
<ul>
<li><a href="https://benzinga.com/25/05/45187521/buffett-tips-his-hat-to-tim-cooks-leadership-at-apple-he-has-made-berkshire-a-lot-more-money-than-ive-ever-made" target="_blank" rel="noreferrer noopener">Warren Buffett Says He Is &#8216;Embarrassed,&#8217; But &#8216;Tim Cook Has Made Berkshire A Lot More Money Than I&#8217;ve Ever Made&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Maxim Elramsisy On Shutterstock.com

Education

France, EU Lure US Researchers With Nearly $567 Million Incentives Amid Trump's Academic Funding Cuts

Raymond James analyst Frank Louthan upgrades Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) from Market Perform to Outperform and announces $4.5 price target.

Upgrades

LUMN

Raymond James Upgrades Lumen Technologies to Outperform, Announces $4.5 Price Target

Cantor Fitzgerald analyst Brett Knoblauch maintains Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Overweight and lowers the price target from $619 to $614.

Cantor Fitzgerald Maintains Overweight on Strategy, Lowers Price Target to $614

Barclays analyst Benjamin Budish maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Underweight and raises the price target from $17 to $19.

Barclays Maintains Underweight on Franklin Resources, Raises Price Target to $19

Barclays analyst Raimo Lenschow maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Overweight and lowers the price target from $60 to $33.

FIVN

Barclays Maintains Overweight on Five9, Lowers Price Target to $33

Henry Schein Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NYSE">HSIC</a>) reported on Monday that its first-quarter adjusted EPS of $1.15, up 4.5% year over year, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noopener">beat</a><a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener"> the consensus of $1.11</a>.
Sales were $3.17 billion, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45189286/henry-schein-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">missing the consensus of $3.23 billion</a>.
<ul>
<li>Constant currency total net sales increased 1.4% compared with the first quarter of 2024. Excluding the impact of personal protective equipment (PPE) and COVID test kits, constant currency sales growth was 2.0%.</li>
<li>As reported, total net sales decreased 0.1% due to a stronger U.S. dollar than last year&#8217;s first quarter.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45157863/cardinal-health-lifts-fy25-eps-outlook-sees-growth-despite-tariff-risks" rel="noreferrer noopener">Cardinal Health Lifts FY25 EPS Outlook, Sees Growth Despite Tariff Risks</a>
&#8220;We are pleased with our first quarter financial results as well as the momentum we are seeing heading into the second quarter and remain confident in the fundamentals of our business,&#8221; said Stanley M. Bergman, chairman of the board and CEO of Henry Schein.
&#8220;We are advancing our BOLD+1 Strategic Plan, which has been refreshed for 2025 to 2027, with our team focused on growing the distribution business through increasing operational efficiency and enhancing customer experience, growing our dental and medical specialty businesses and corporate brand products, and further developing our digital footprint and digital solutions,&#8221; Bergman added.
<ul>
<li>Global Distribution and Value-Added Services sales reached $2.68 billion, up 0.8% in constant currencies compared with the first quarter of 2024, and increased 1.5%, excluding the impact of PPE and COVID test kits. As-reported sales decreased 0.7%.</li>
<li>Global Specialty Products sales were $367 million, 4.3% in constant currencies compared with the first quarter of 2024, reflecting continued growth in implant and biomaterial sales and acquisition growth. As-reported sales increased 2.0%.</li>
<li>Global Technology sales were $162 million, up 3.4% in constant currencies compared with the first quarter of 2024. Strong sales growth in practice management systems, including Dentrix Ascend and Dentally cloud-based solutions, as well as in revenue cycle management products, was partially offset by lower sales of certain legacy products. As-reported sales increased 2.9%.</li>
</ul>
Restructuring Plan: During the first quarter of 2025, the company recorded $25 million in restructuring costs and expects to achieve annual run-rate savings at the high end of its $75 million to $100 million <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43947748/henry-schein-q4-earnings-and-outlook-miss-expectations-restructures-for-growth" rel="noreferrer noopener">goal by the end of 2025</a>.
Guidance:&nbsp;Henry Schein affirms 2025 adjusted EPS of $4.80-$4.94 versus a consensus of $4.86. The company also expects sales growth of approximately 2%—4% over 2024, of $12.43 billion—$13.18 billion versus a consensus of $13 billion.
The company&#8217;s 2025 adjusted EBITDA&nbsp;growth is unchanged and is expected to increase by mid-single digits compared with 2024.
The company says the guidance also assumes that foreign currency exchange rates remain generally consistent with current levels and that additional tariffs will not be introduced.
Price Action: HSIC stock is trading 1.30% lower at $64.46 during the premarket session at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45179419/estee-lauders-beauty-gains-cant-offset-global-headwinds-says-analyst" target="_blank" rel="noreferrer noopener">Estée Lauder&#8217;s Beauty Gains Can&#8217;t Offset Global Headwinds, Says Analyst</a></li>
</ul>
Photo: Shutterstock

Earnings

Large Cap

Guidance

Health Care

HSIC

Henry Schein's Reports Mixed Bag Q1 Earnings, CEO Confident In Business Fundamentals

ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease.
This RTF letter was received despite unanimous guidance and encouragement from the agency&#8217;s leadership, including from CBER, CDER, and OCE, to submit this sBLA at the in-person <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45189879/immunitybio-requests-an-urgent-meeting-with-fda-to-address-the-change-in-the-agencys-unambiguous-g" rel="noreferrer noopener">January 2025 meeting</a>.
At this meeting, all key decision makers were specifically asked and unanimously confirmed that ImmunityBio should submit the sBLA as soon as possible based on the data in the single-arm trial.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44174118/immunitybio-analyst-predicts-strong-2025-for-new-bladder-cancer-drug" rel="noreferrer noopener">ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug</a>
Relying on this unanimous guidance, the company submitted the sBLA in March 2025. The company has already requested an urgent meeting to resolve the inconsistencies between the directives provided at the January Meeting and receipt of the RTF letter.
ANKTIVA was approved by the FDA in 2024 with BCG for BCG unresponsive NMIBC with <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38380405/fda-approves-immunitybios-bladder-cancer-drug-stock-rallies" rel="noreferrer noopener">Papillary tumors&nbsp;with&nbsp;CIS</a>.
In the same clinical trial (QUILT-3.032), the long-term results of patients with Papillary tumors&nbsp;without&nbsp;CIS (Cohort B) were submitted as an sBLA. The RTF letter referenced herein does not impact this prior approval of CIS +/—papillary in BCG-unresponsive patients.
Data was also presented on the long-term follow-up Phase 1 results, which demonstrated Complete Response and Disease-Free Survival in both CIS and Papillary disease, with patients in an ongoing cystectomy-free state at 10 years.
In addition, the disease-specific overall survival rate of 99% at 12 months and 96% at 36 months in the BCG unresponsive patients with Papillary disease <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43038889/immunitybio-stock-trading-higher-on-updates-from-bladder-cancer-trials-details" rel="noreferrer noopener">without CIS was discussed</a>.
In March 2025, the company completed its submission to the FDA of the sBLA for the use of ANKTIVA plus BCG in BCG-unresponsive NMIBC in the papillary indication.
The company and its consultants, who attended the January 2025 meeting, were shocked by this inconsistent response and have requested an urgent meeting with the FDA to resolve this issue.
In April last year, ImmunityBio announced the overall survival results of Anktiva combined with checkpoint inhibitors in non-small <a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38421500/immunitybio-announces-positive-overall-survival-results-of-anktiva-combined-with-checkpoint-inhibi" rel="noreferrer noopener">cell lung cancer</a>.
QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy.
Price Action: At the last check on Monday, IBRX stock was down 16.50% to $2.12 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45179310/analyst-says-microstrategy-inc-s-bold-bitcoin-strategy-still-has-room-to-run" target="_blank" rel="noreferrer noopener">Analyst Says MicroStrategy Inc.&#8217;s Bold Bitcoin Strategy Still Has Room To Run</a></li>
</ul>

Movers

IBRX

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

Cantor Fitzgerald analyst Jonathan Ruykhaver reiterates JFrog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) with a Overweight and maintains $46 price target.

Reiteration

FROG

Cantor Fitzgerald Reiterates Overweight on JFrog, Maintains $46 Price Target

Barclays analyst Betty Jiang maintains Exxon Mobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) with a Overweight and lowers the price target from $130 to $127.

Barclays Maintains Overweight on Exxon Mobil, Lowers Price Target to $127

BMO Capital analyst Brian Pitz reiterates Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Outperform and lowers the price target from $240 to $236.

TTWO

BMO Capital Reiterates Outperform on Take-Two Interactive, Lowers Price Target to $236

President Donald Trump says he will personally phone chief executives who make business moves he dislikes, a tactic he deployed last week with Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder Jeff Bezos over planned tariff disclosures on the e‑commerce giant's site.
What Happened: In an <a href="https://www.nbcnews.com/politics/donald-trump/trump-call-ceos-plans-prices-tariffs-rcna204702">interview</a> on NBC's "Meet the Press," Trump recounted calling Bezos after Punchbowl News reported Amazon might label import fees tied to the administration's new 145% tariff on Chinese goods. "He's just a very nice guy," Trump said. "I asked him about [the <a href="https://www.benzinga.com/media/25/04/45086459/amazon-pressures-suppliers-for-discounts-may-show-tariff-related-costs-on-haul-site">tariff disclosure</a>]. He said, ‘Well, I don't want to do that,' and he took it off immediately." Amazon later confirmed the low‑cost Haul storefront had only "considered" the idea and dropped it.
Trump insisted he would ring any CEO whose actions he deemed "hurtful to the country." He framed tariffs not as consumer taxes but as incentives to reshore manufacturing. "The company eats the tariff," he told moderator Kristen Welker.
Asked whether fewer toys on store shelves would mark success, Trump replied, "Maybe the children will have <a href="https://www.benzinga.com/trading-ideas/25/05/45144516/trump-a-grinch-or-santa-for-christmas-children-will-have-two-dolls-instead-of-30-dolls">two dolls instead of thirty</a>. … We don't have to waste money on a trade deficit with China for junk we don't need."
See also: <a href="https://www.benzinga.com/personal-finance/25/05/45192749/ray-dalio-says-chasing-wealth-without-purpose-is-a-tragedy-dont-make-money-itself-the-goal">Ray Dalio Says Chasing Wealth Without Purpose Is A Tragedy: &#8216;Don&#8217;t Make Money Itself The Goal&#8217;</a>
Why It Matters: Economist Peter Schiff <a href="https://www.benzinga.com/news/25/05/45152587/trumps-call-to-jeff-bezos-over-amazons-tariff-display-earns-peter-schiffs-ire-type-of-stuff-you-migh">blasted Trump's call</a> to Jeff Bezos, calling it "the type of stuff you might expect to see in China." Sen. Elizabeth Warren followed up with a pointed letter to the Amazon founder, asking if Trump's angry phone call pushed Bezos to kill the tariff‑label plan in exchange for "promises or favors." <a href="https://www.benzinga.com/government/25/05/45128591/elizabeth-warren-asks-jeff-bezos-if-trump-threatened-retaliation-or-offered-favors-after-calling-him-very-nice-for-amazons-reversal-on-showing-tariff-fees">Warren warned</a> that scrubbing tariff costs "keeps consumers in the dark" and could signal a corrupt quid‑pro‑quo between Big Tech and the White House.
Days later, Trump marked his first 100 days back in office by welcoming more than <a href="https://www.benzinga.com/markets/equities/25/04/45060579/nvidia-johnson-johnson-hyundai-toyota-softbank-ceos-to-join-trump-at-white-house-as-he-touts-inv">two dozen corporate chiefs</a> to the White House. He used the "Investing in America" event to spotlight new spending commitments from powerhouses such as NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Hyundai Motor (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HYMTF#OTC">HYMTF</a>), Toyota Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>), and SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>), according to officials who briefed Reuters.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45192936/wall-street-veteran-investor-lowers-recession-risk-as-us-china-trade-war-cools">Wall Street Veteran Investor Lowers Recession Risk As US-China Trade War Cools</a>

Politics

AMZN

HYMTF

NVDA

SFTBF

Donald Trump Vows To 'Call' Up CEOs Who Make Business Moves That Displease Him, Explains Why He Phoned Jeff Bezos To Scrap Amazon's Tariff Disclosure

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Equal-Weight and raises the price target from $90 to $93.

DXCM

Barclays Maintains Equal-Weight on DexCom, Raises Price Target to $93

Press Releases

Pinstripes Holdings, Inc. to Announce Fiscal Fourth Quarter and Fiscal Year 2024 Results on June 27, 2024

Pinstripes Reports Fiscal Fourth Quarter, Fiscal Year 2024 Results, And Fiscal 2025 Guidance

Pinstripes Holdings, Inc. to Announce Fiscal First Quarter 2025 Results on September 4, 2024

Pinstripes Reports Fiscal 2025 First Quarter Results And Updated Fiscal 2025 Guidance

Pinstripes Walnut Creek to Open on November 15 at Broadway Plaza

Pinstripes Holdings, Inc. to Announce Fiscal Second Quarter 2025 Results on November 26, 2024

Pinstripes Reports Fiscal 2025 Second Quarter Results

Pinstripes Holdings, Inc. to Announce Fiscal Third Quarter 2025 Results on February 19, 2025

Pinstripes Reports Fiscal 2025 Third Quarter Results

Pinstripes Announces Letter of Intent for Strategic Recapitalization with Oaktree, Providing the Company with Additional Capital to Fund Operations and Growth

Comments

Pinstripes Holdings

Pinstripes Holdings (PNST) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO